| | |
| Clinical data | |
|---|---|
| Other names | Chloro-IB-MECA; 2-Cl-IB-MECA |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.162.091 |
| Chemical and physical data | |
| Formula | C18H18ClIN6O4 |
| Molar mass | 544.73 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease, [1] liver cancer, [2] and pancreatic cancer. [3]